Press Releases

Press Releases

LEXINGTON, MA – February 13, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that their Simoa HD-1 Analyzer has been named a 2015 award finalist by the internationally…
LEXINGTON, MA – June 15, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced an alliance with PBL Assay Science (PBL), naming the Company as a Preferred Partner for assay research…
LEXINGTON, MA – October 28, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the launch of Simoa 2.0, its next-generation ultrasensitive immunoassay platform. Simoa 2.0…
February 10, 2016
Quanterix announces an alliance with Frontage Laboratories, naming the Company as a Preferred Partner for assay research and development. Leveraging Simoa’s sensitivity and revolutionary digital approach for assay development and research, Frontage will have the ability to enter new markets and…
February 3, 2017
HOUSTON and LEXINGTON, Mass.—February 3, 2017—Quanterix Corporation, a company digitizing biomarker analysis to advance the science of precision health, today announced that Kevin Hrusovsky, Quanterix Chief Executive Office
July 6, 2017
Breakthrough Research Published in PLOS ONE Demonstrates Quantitative, PCR-Free Detection of MicroRNA
CAMBRIDGE, MA – February 22, 2011 – Quanterix Corporation, enabling a new generation of diagnostic tests based on revolutionary Single Molecule Array (SiMoA™) technology, today announced that it has entered into an evaluation agreement with Novartis Diagnostics on the potential use of Quanterix’s…
CAMBRIDGE, MA – October 13, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results from a clinical evaluation of its Prostate Specific Antigen (PSA) test, a fifth–…
LEXINGTON, MA – August 7th, 2012 – Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it had been issued a US Patent for ultra-sensitive detection of molecules. The patent issue marks another milestone for Quanterix and highlights the achievements…